| abstract |
The present invention relates to a series of tyrosine kinases associated with diseases related to inflammatory conditions, autoimmune diseases, proliferative diseases, allergies, transplant rejection, diseases associated with impaired cartilage rotation, congenital cartilaginous deformities, and / or overdoses of IL6 or interferon 0.0 > (JAK) < / RTI > which is an inhibitor of kinase kinase (JAK). In particular, the compounds of the invention inhibit JAK1 and / or JAK2 and / or JAK3 sub-sequences. The present invention also relates to compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, their tautomeric forms, and their pharmaceutically acceptable salts. Formula 1 |